

FORM 13-502F1
CLASS 1 REPORTING ISSUERS – PARTICIPATION FEE

Reporting Issuer Name: Pacgen Biopharmaceuticals Corporation

Fiscal year end date used to calculate capitalization: March 31, 2006

Market value of listed or quoted securities:

Total number of securities of a class or series outstanding at the issuer's most recent fiscal year end N/A (i)

Simple average of the closing price of that class or series as of the last trading day of each month of the fiscal year (See clauses 2.11(a)(ii)(A) and (B) of the Rule) N/A (ii)

Market value of class or series (i) X (ii) = N/A (A)

(Repeat the above calculation for each class or series of securities of the reporting issuer that are listed or quoted on a marketplace in Canada or the United States of America at the end of the fiscal year)

N/A (B)

Market value of other securities:

(See paragraph 2.11(b) of the Rule)

(Provide details of how value was determined)

Total number of securities of a class or series which will be outstanding upon the completion of the issuer's prospectus offering 32,378,887 (I)

Offering price at which prospectus shares are being offered \$1.05 (II)

Market value of class or series (I) X (II) = \$33,997,831 (C)

(Repeat for each class or series of securities) N/A (D)

Capitalization

(Add market value of all classes or series of securities) (A)+(B)+(C)+(D) = \$33,997,831

Participation Fee

(From Appendix A of the Rule, select the participation fee beside the capitalization calculated above) \$1,300

New reporting issuer's reduced participation fee, if application

(See section 2.6 of the Rule)

Participation fee (\$1,300) x Number of entire months remaining in the issuer's
fiscal year (4) \$433.33
12

Late Fee, if applicable N/A
(As determined under section 2.5 of the Rule)